Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance

Triple negative breast cancer (TNBC) displays a high aggressive behavior, tendency to relapse and early metastasize, leading to poor prognosis. The lack of estrogen receptors, and human epidermal growth factor receptor 2, prevents the use of endocrine or molecular targeted therapy, being therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Human cell : official journal of Human Cell Research Society 2023-05, Vol.36 (3), p.1108-1119
Main Authors: Campagna, Roberto, Pozzi, Valentina, Giorgini, Sara, Morichetti, Doriana, Goteri, Gaia, Sartini, Davide, Serritelli, Emma Nicol, Emanuelli, Monica
Format: Article
Language:English
Subjects:
Aryldialkylphosphatase - genetics
Biomedical and Life Sciences
Breast cancer
Cancer therapies
Carcinogenesis
Case-Control Studies
Cell Biology
Cell growth
Cell proliferation
Chemoresistance
Chemotherapy
Cytotoxicity
Drug Resistance, Neoplasm - genetics
Enzymes
ErbB-2 protein
Estrogen receptors
Gynecology
Humans
Life Sciences
Oncology
Paraoxonase
Radiation therapy
Reproductive Medicine
Research Article
Stem Cells
Surgery
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - genetics
Triple Negative Breast Neoplasms - metabolism
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple negative breast cancer (TNBC) displays a high aggressive behavior, tendency to relapse and early metastasize, leading to poor prognosis. The lack of estrogen receptors, and human epidermal growth factor receptor 2, prevents the use of endocrine or molecular targeted therapy, being therapeutical options for TNBC managements mostly limited to surgery, radiotherapy and mainly chemotherapy. While an important number of TNBCs initially responds to chemotherapy, they are prone to develop chemoresistance over the time. Thus, there is an urgent need to identify novel molecular targets to improve the outcome of chemotherapy in TNBC. In this work we focused on the enzyme paraoxonase-2 (PON2) which has been reported to be overexpressed in several tumors contributing to cancer aggressiveness and chemoresistance. Through a case–control study, we analyzed PON2 immunohistochemical expression in breast cancer molecular subtypes Luminal A, Luminal B, Luminal B HER2+, HER2 + and TNBC. Subsequently, we evaluated the in vitro effect of PON2 downregulation on cell proliferation and response to chemotherapeutics. Our results showed that the PON2 expression levels were significantly upregulated in the infiltrating tumors related to the subtypes Luminal A, HER2+ and TNBC compared to the healthy tissue. Furthermore, PON2 downregulation led to a decrease in cell proliferation of breast cancer cells, and significantly enhanced the cytotoxicity of chemotherapeutics on the TNBC cells. Although further analyses are necessary to deeply understand the mechanisms by which the enzyme could participate to breast cancer tumorigenesis, our results seem to demonstrate that PON2 could represent a promising molecular target for TNBC treatment.
ISSN:1749-0774
0914-7470
1749-0774
DOI:10.1007/s13577-023-00892-9